[1] Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association[J]. Circulation, 2014, 129(3): e28-e292.
[2] Kahr PC, Diller GP. Almanac 2014: congenital heart disease[J]. Heart, 2015, 101(1): 65-71.
[3] 毛红柳,刘兴元.先天性心脏病相关GATA5基因突变研究[J].国际心血管病杂志, 2013, 40(3): 173-177.
[4] 徐 蕾, 袁 方, 李若谷, 等. 先天性房间隔缺损相关GATA6基因新突变的识别[J]. 国际心血管病杂志, 2014, 41(2): 121-124.
[5] Fahed AC, Gelb BD, Seidman JG, et al. Genetics of congenital heart disease: the glass half empty[J]. Circ Res, 2013, 112(4): 707-720.
[6] Andersen TA, Troelsen Kde L, Larsen LA. Of mice and men: molecular genetics of congenital heart disease[J]. Cell Mol Life Sci, 2014, 71(8): 1327-1352.
[7] Semenza GL. Hypoxia-inducible factor 1 and cardiovascular disease[J]. Annu Rev Physiol, 2014, 76: 39-56.
[8] Compernolle V, Brusselmans K, Franco D, et al. Cardia bifida, defective heart development and abnormal neural crest migration in embryos lacking hypoxia-inducible factor-1alpha[J]. Cardiovasc Res, 2003, 60(3): 569-579.
[9] Ye Y, Wang M, Hu S, et al. Hypoxia-inducible factor-1α C1772T polymorphism and cancer risk: a meta-analysis including 18,334 subjects[J]. Cancer Invest, 2014, 32(4): 126-135.
[10] Nagy G, Kovacs-Nagy R, Kereszturi E, et al. Association of hypoxia inducible factor-1 alpha gene polymorphism with both type 1 and type 2 diabetes in a Caucasian(Hungarian)sample[J]. BMC Med Genet, 2009, 10: 79.
[11] Resar JR, Roguin A, Voner J, et al. Hypoxia-inducible factor 1alpha polymorphism andcoronary collaterals in patients with ischemic heart disease[J]. Chest, 2005, 128(2): 787-791.
[12] Lin WP, Wang XJ, Wang CR, et al. Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to LDD in Chinese cohort[J]. PLoS One, 2013, 8(8): e73158.
[13] 祁 琳,张晓雷,毛立群,等.HIF-1与低氧性疾病关系的研究进展[J].武警后勤学院学报(医学版),2013,22(4):330-333.
[14] 李海生,朱玲玲,范 明.低氧诱导因子-1 结构、活性调节及其靶基因的研究进展[J].军事医学科学院院刊,2004,28(2):183-186.
[15] Hu X, Fang Y, Zheng J, et al. The association between HIF-1α polymorphism and cancer risk: a systematic review and meta-analysis[J].Tumour Biol, 2014, 35(2): 903-916.
[16] Tanimoto K, Yoshiga K, Eguchi H, et al. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance[J]. Carcinogenesis, 2003, 24(11): 1779-1783.
[17] Fu XS, Choi E, Bubley GJ, et al. Identification of hypoxia-inducible factor-1alpha(HIF-1alpha)polymorphism as a mutation in prostatecancer that prevents normoxia-induced degradation[J]. Prostate, 2005, 63(3): 215-221.